News
Press releases (by year)
2013
Cardio3 BioSciences raises €19 million through a Private Placement FR NL
Results from Cardio3BioSciences C-Cure® Trial published in the Journal of the American College of Cardiology FR NL
2012
Cardio3 BioSciences Receives Authorization to Begin World's First Phase III Clinical Trial in Regenerative Medicine for Heart Failure FR NL
Cardio3 BioSciences Appoints Dr. Alexander Milstein as Vice President of Clinical Development
Cardio3 BioSciences Announces CE Marking for its C-Cath® Injection Catheter FR NL
Cardio3 BioSciences Granted GMP Certification FR NL
Cardio3 BioSciences Receives ISO-13485 Certification
Cardio3 BioSciences Secures Additional €3.1 million in Non-dilutive Funding from the Walloon Region and the European Commission
FR NL
2011
Cardio3 BioSciences Establishes US Subsidiary in Rochester, MN
Belgian economic mission in the U.S. is a success for Cardio3 BioSciences Cardio3 BioSciences and ATMI, Inc.Sign a Letter of intent FR NL
Mission économique et commerciale présidée par SAR le Prince Philippe aux Etats-Unis NL
Cardio3 BioSciences Presents C-Cure® Phase II Clinical Trial Results at the EuroPCR Meeting
Cardio3 BioSciences Announces International C-Cure® Phase II Clinical Trial at the 60th Annual American College of Cardiology Meeting FR NL
Cardio3 BioSciences Announces its new Board Members FR NL
2010
Cardio3 BioSciences Announces Significant Progress in its Programme for the Treatment of Acute Myocardial Infarction FR NL
Cardio3 BioSciences Announces Positive Outcome of the C-Cure Phase II Clinical Trial in Heart Failure Patients FR NL
Cardio3 BioSciences Publishes the Science Basis for C-Cure® in JACC FR NL
Cardio3 BioSciences Reports Positive Three-Month Data from its Clinical Trial of C-Cure® in Heart Failure FR NL
Cardio3 BioSciences Announces Promising Pre‐Clinical Data for Proprietary C‐Cath® Catheter FR NL
2009
Cardio3 BioSciences at ESC Barcelona
Cardio3 BioSciences To Present At Forthcoming BioEquity Europe 2009 Meeting
Cardio3 BioSciences at EuroPCR Barcelona
Cardio3 BioSciences Treats Its First Patient with C-Cure®,
a Second-Generation Stem Cell Derived Therapy for Heart Failure FR NL
Cardio3 BioSciences Raises €13.7 million in Series B Fundraising and Grant Funding
2008
Events
2013
June 4
IchemE meeting, Chemistry Centre, Burlington House, London, UK
Presenter: Peter de Waele, VP Research & Development
Dare & time : June 4,
Title: Product development in regenerative medicine
May 21-23
World Stem Cells and Regenerative Medicine Congress, Victoria Park Plaza, London, UK
Presenter: Roland Gordon-Beresford, Regulatory Affairs & IP Sr Director
Date & time: Monday, May 21, 15:35
Title: Balancing financial constraints and regulatory requirements within a clinical development plan for cell therapies
April 22-25
BIO International Convention, Chicago, U.S.
January 23-25
Eighth International Conference on Cell Therapy for Cardiovascular Disease
Panelist: Aymeric Seron, Program Manager
Date & Time : Wednesday 23, 11:15 AM
Title : Industry Panel I. Cell Delivery and Acute Repair Technologies
January 28-30
Phacilitate’s 9th Annual Cell & Gene Therapy Forum
Presenter: Christian Homsy, CEO
Date & Time: Monday 28, 5:25 PM
Title: The journey from bench to Phase III, lessons from the development of CQR-1
2012
September 10-11
IBC’S Cell Therapies & Regenerative Therapies, Arlington, VA, US.
Presenter: Christian Homsy, CEO
Title : Cardiopoietic Stem Cells for heart regeneration – From Bench to Phase III
June 18-21
BIO International Convention, Boston Convention & Exhibition Center, MA, U.S.
Presenter: Christian Homsy, CEO
June 17
Biowin-Awex Satellite Event to Bio International Convention, Sheraton Boston Copley, Boston, MA, U.S
Presenter : Christian Homsy, CEO
Date & Time: Sunday, June 17, 2:30 pm
Title: Innovation Partnerships as boosters for global business in life sciences
May 24-26
Cardiac Regenerative and Vascular Biology Conference 2012, San Servolo, Venice, Italy
Presenter: Jozef Bartunek, Cardiovascular Center Aalst, Belgium
Date & Time: Thursday, May 24, 2:30 pm
Title: Guided Cardiopoietic Mesenchymal Stem Cells in Ischemic Cardiomyopathy Phase II Trial
May 24
Knowledge for Growth, ICC Ghent, Belgium
Presenter: Christian Homsy, CEO
Date & Time: Thursday, May 24, 11:30 am
Title: Innovative regenerative & protective therapies to treat cardiac diseases : the evolution towards Personalized Medicine
May 21-23
World Stem Cells and Regenerative Medicine Congress, Victoria Park Plaza, London, UK
Presenter: Christian Homsy, CEO
Date & time: Monday, May 23, 11:20 am
Title: Organ-specified cardiopoietic stem cell therapy and related technologies for regenerative cardiovascular medicine
May 19-22
Heart Failure Congress, Belgrade, Serbia
Presenter: Andre Terzic, Mayo Clinic, Minnesota, US
Date & Time: Sunday, May 20, 4:30 pmTitle: The C-CURE Multicenter Randomized Trial. - Cardiopoietic Stem Cell Transplantation in Heart Failure.
May 15-18
EuroPcR, Paris, France
Poster C-Cath® Intramyocardial Injection Catheter
2011
Cardio3 Biosciences will be at l’Aula Magna in Louvain-la-Neuve
Friday 14, and Saturday October 15th for the event "Europe en BW"
Mission économique et commerciale présidée par SAR le Prince Philippe aux Etats-Unis NL
22-30 June 2011- New York – Washington DC – Boston, US
Bio
27-30 June 2011 – Washington DC, US
EuroPCR
17-20 May – Paris, France
ACC FR NL
2-5 April – New Orleans, US
Bio Capital Europe
31 March – Amsterdam, Netherlands
2010
JDE
3 October, Mont-Saint-Guibert, Belgium
World Expo Shanghai – Belgian Pavilion
1 May -31 October – Shanghai - China
Epic
12 June – London, UK
Bio
3-6 May – Chicago, US
2009
ESC
29 August – 2 September – Barcelona, Spain
EuroPCR
19-22 May- Barcelona, Spain
January 23-25
Eighth International Conference on Cell Therapy for Cardiovascular Disease
Panelist: Aymeric Seron, Program Manager
Date & Time : Wednesday 23, 11:15 AM
Title : Industry Panel I. Cell Delivery and Acute Repair Technologies
January 28-30
Phacilitate’s 9th Annual Cell & Gene Therapy Forum
Presenter: Christian Homsy, CEO
Date & Time: Monday 28, 5:25 PM
Title: The journey from bench to Phase III, lessons from the development of CQR-1
